NANCEY , Stéphane

Summary Introduction Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti‐TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification...

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to...

International audience

Background - In case of a loss of response to adalimumab, some patients with Crohn's disease may derive benefit from increasing the dosing frequency to 40 mg weekly. Efficacy and safety of adalimumab 80 mg weekly remain unknown. Methods - From February 2011 to September 2012, all adults who had active Crohn's disease, defined at least by...